S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)
S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)
S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)
S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)

Kinnate Biopharma (KNTE) Stock Price, News & Analysis

$2.19
-0.10 (-4.37%)
(As of 10:37 AM ET)
Compare
Today's Range
$2.18
$2.28
50-Day Range
$1.07
$2.50
52-Week Range
$1.04
$8.17
Volume
88,565 shs
Average Volume
546,395 shs
Market Capitalization
$103.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.60

Kinnate Biopharma MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
557.7% Upside
$14.60 Price Target
Short Interest
Bearish
5.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.50) to ($1.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

394th out of 942 stocks

Pharmaceutical Preparations Industry

155th out of 424 stocks


KNTE stock logo

About Kinnate Biopharma Stock (NASDAQ:KNTE)

Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

KNTE Stock Price History

KNTE Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Wedbush Downgrades Kinnate Biopharma (KNTE)
Kinnate Biopharma (KNTE) Receives a Buy from H.C. Wainwright
KRBP Kiromic BioPharma, Inc.
See More Headlines
Receive KNTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kinnate Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KNTE
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.60
High Stock Price Target
$26.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+537.6%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-116,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.06 per share

Miscellaneous

Free Float
27,467,000
Market Cap
$107.89 million
Optionable
Not Optionable
Beta
1.34
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report














KNTE Stock Analysis - Frequently Asked Questions

Should I buy or sell Kinnate Biopharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kinnate Biopharma in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KNTE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KNTE, but not buy additional shares or sell existing shares.
View KNTE analyst ratings
or view top-rated stocks.

What is Kinnate Biopharma's stock price target for 2024?

5 analysts have issued 12 month price targets for Kinnate Biopharma's shares. Their KNTE share price targets range from $4.00 to $26.00. On average, they expect the company's share price to reach $14.60 in the next year. This suggests a possible upside of 557.7% from the stock's current price.
View analysts price targets for KNTE
or view top-rated stocks among Wall Street analysts.

How have KNTE shares performed in 2023?

Kinnate Biopharma's stock was trading at $6.10 at the beginning of the year. Since then, KNTE stock has decreased by 63.6% and is now trading at $2.22.
View the best growth stocks for 2023 here
.

When is Kinnate Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our KNTE earnings forecast
.

How were Kinnate Biopharma's earnings last quarter?

Kinnate Biopharma Inc. (NASDAQ:KNTE) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.65) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.04.

When did Kinnate Biopharma IPO?

(KNTE) raised $170 million in an initial public offering (IPO) on Thursday, December 3rd 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, SVB Leerink, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO.

Who are Kinnate Biopharma's major shareholders?

Kinnate Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Lynx1 Capital Management LP (4.24%), Acadian Asset Management LLC (1.56%), Jacobs Levy Equity Management Inc. (0.95%), Citigroup Inc. (0.89%), Citigroup Inc. (0.89%) and Rock Springs Capital Management LP (0.86%). Insiders that own company stock include Carl L Gordon, James B Tananbaum, Orbimed Advisors Llc and Richard Thomas Williams.
View institutional ownership trends
.

How do I buy shares of Kinnate Biopharma?

Shares of KNTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KNTE) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -